A Newly Formed and Ruptured Atheromatous Plaque within Neointima after Drug-Eluting Stent Implantation: 2-Year Follow-Up Intravascular Ultrasound and Optical Coherence Tomography Studies

Chang-Myung Oh, Jeonggeun Moon, Hee Tae Yu, Ji-Yong Jang, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, and Myeong-Ki Hong
Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, Korea.

Received: July 23, 2010
Revised: August 26, 2010
Accepted: September 2, 2010
Corresponding author: Dr. Myeong-Ki Hong, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-8458, Fax: 82-2-393-2041 E-mail: mkhong61@yuhs.ac

- The authors have no financial conflicts of interest.

Late stent thrombosis (LST) which is a life threatening complication has emerged as a serious problem of drug-eluting stents (DES). Several studies have suggested that incomplete neointimal coverage of stent struts contributes to LST. Progressive atherosclerosis within the neointima is another possible cause of LST, but this phenomenon has seldom been reported in DES. We present a case of LST following DES implantation after a period of 28 months due to ruptured atheromatous plaque, despite complete neointimal coverage of stent struts proven by optical coherence tomography.

Key Words: Drug-eluting stents, thrombosis, optical coherence tomography

INTRODUCTION

Drug eluting stent (DES) has successfully been introduced to interventional cardiology in order to prevent in-stent restenosis. Nevertheless, concerns about the safety of DES still exist. Especially, late stent thrombosis (LST) is an unsolved problem in the DES era, which was rarely seen with bare metal stents (BMS). The risk of LST is associated with patient and lesion characteristics, non-compliance of anti-platelet drugs and incomplete stent apposition, number and the length of stents, coronary dissection, etc. Incomplete neointimal coverage of stent struts is the most important predictor of LST. We report a case of LST despite complete neointimal coverage on well-opposed stent struts and continued dual anti-platelet therapy more than 1 year.

CASE REPORT

A 57-year-old male with a history of hypertension, diabetes mellitus, normal renal function and a 60 pack years smoking received percutaneous coronary interven-
tion at the right coronary artery with the impression of stable angina pectoris in September 2007 (Fig. 1). Two sirolimus-eluting stents (SES) \[3.0×28 \text{ mm, } 2.75×28 \text{ mm (Cypher, Cordis Corp., Johnson & Johnson Co., Warren, New Jersey, USA)}\] were implanted at the distal part of the right coronary artery. Transthoracic echocardiography demonstrated normal left ventricular systolic function (ejection fraction=56%) with regional wall motion abnormality at the inferior wall. One-year follow-up angiogram showed that 2 stents were all patent. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) revealed complete neointimal coverage of stent struts (Fig. 2).

Until recently, he had good compliance with dual antiplatelet agents and other medications, and did not suffer from chest pain. However, the result of treadmill test was positive. Therefore, he underwent another follow-up angiogram to evaluate silent ischemia in January 2010. The follow-up angiogram revealed 2 patent stents implanted in the right coronary artery. However, abnormal contrast filling

![Image](image1)

**Fig. 1.** Initial coronary angiogram of the RCA. (A) Coronary angiogram shows significant luminal narrowing at the distal RCA. (B) After stent implantation, there is a minimal residual stenosis. RCA, right coronary artery.

![Image](image2)

**Fig. 2.** Coronary angiogram and OCT findings at 12-month follow-up. (A) Coronary angiogram shows no restenosis in the stented segment. (B, C and D) The OCT shows complete neointimal coverage of stent struts. OCT, optical coherence tomography.

![Image](image3)

**Fig. 3.** (A) The 2nd follow-up angiogram at 28 months after stent implantation shows abnormal contrast filling in a previously implanted stent (see arrow). (B, C and D) IVUS and OCT images reveal newly formed and ruptured atheromatous plaque within neointima. Arrowheads indicate stent strut. IVUS, intravascular ultrasound; OCT, optical coherence tomography.
defect was observed within the previously stented segments (arrow in Fig. 3A). IVUS and OCT were performed to elucidate the characteristics of the abnormal contrast filling defect. Both studies revealed a newly formed and ruptured atheromatous plaque within the neointima over the stent struts (IVUS and OCT) (Fig. 3B, C and D). He was successfully treated with percutaneous coronary intervention and discharged on medications of aspirin (100 mg/day), clopidogrel (75 mg/day), atorvastatin (10 mg/day) and atenolol (25 mg/day).

**DISCUSSION**

LST after DES implantation has been thought to be caused by poorly formed neointima and incomplete neointimal coverage over DES struts. In a recent study using angioscopy, however, a newly formed and thrombogenic atherosclerotic yellow neointima after DES implantation was reported. This phenomenon may be an another cause for late stent thrombosis after DES implantation. Stent thrombosis and myocardial infarction caused by restenosis during extended follow-up after bare metal stent implantation have been reported and might be explained by newly formed and progressive atherosclerosis within neointima. However, this phenomenon has seldom been reported in DES. Atherosclerotic change within neointima after bare metal stent implantation usually occurs after 5 years. The intracoronary images of our patient illustrate a newly formed and ruptured atheromatous plaque within neointima after DES implantation in a relatively short period (less than 3 years after DES implantation). A recent pathologic study showed that atherosclerotic lesions progress more rapidly within SES than within BMS. In the autopsy study by Nakazawa, et al. the atherosclerotic change in SES was seen in more than 40 percent of cases by 9 months, but the change in BMS occurred only after 2 years. We think that early atherosclerosis is a possible mechanism in our case. This was an unexpected finding and gave us a very helpful insight for better treatment and monitoring in patients with DES implantation.

**REFERENCES**

1. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
2. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
3. Kim U, Kim JS, Kim JS, Lee JM, Son JW, Kim J, et al. The initial extent of malapposition in ST-elevation myocardial infarction treated with drug-eluting stent: the usefulness of optical coherence tomography. Yonsei Med J 2010;51:332-8.
4. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
5. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007;28:961-7.
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
7. Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging 2009;2:616-24.
8. Doyle B, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-8.
9. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging 2009;2:625-8.